Amneal Pharmaceuticals, Inc. (AMRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5B 3B 4.5B Q3 '24: 2.7B Q4 '24: 2.8B Q1 '25: 2.8B Q2 '25: 2.9B Q3 '25: 2.9B Q4 '25: 3B Q1 '26: 3B Q2 '26: 3.1B Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 500M 1B 1.5B Q3 '24: 947.4M Q4 '24: 1B Q1 '25: 1B Q2 '25: 1.1B Q3 '25: 1.1B Q4 '25: 1.1B Q1 '26: 1.2B Q2 '26: 1.2B Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Income TTM

0 200M 400M 600M Q3 '24: 187.7M Q4 '24: 249.3M Q1 '25: 360.4M Q2 '25: 376.3M Q3 '25: 357.9M Q4 '25: 394.1M Q1 '26: 435.5M Q2 '26: 453.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-210M -140M -70M 0 70M 140M 210M Q3 '24: -184.5M Q4 '24: -116.9M Q1 '25: -13M Q2 '25: 3.4M Q3 '25: 5.9M Q4 '25: 72.1M Q1 '26: 122.1M Q2 '26: 157.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 700M 1.4B 2.1B Q3 '24: 1.7B Q4 '24: 1.8B Q1 '25: 1.8B Q2 '25: 1.8B Q3 '25: 1.9B Q4 '25: 1.9B Q1 '26: 1.9B Q2 '26: 1.9B Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

0 150M 300M 450M Q3 '24: 312.8M Q4 '24: 295.1M Q1 '25: 306.9M Q2 '25: 351.1M Q3 '25: 327.8M Q4 '25: 340M Q1 '26: 305.8M Q2 '26: 200.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

0 100M 200M 300M Q3 '24: 266.2M Q4 '24: 243.2M Q1 '25: 251M Q2 '25: 283M Q3 '25: 264.3M Q4 '25: 269.9M Q1 '26: 240.8M Q2 '26: 127.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '24: 307.3M Q2 '24: 319M Q3 '24: 309.6M Q1 '25: 324M Q2 '25: 322.4M Q3 '25: 324.8M Q1 '26: 328.9M Q2 '26: 328.1M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.90 -0.60 -0.30 0.00 0.30 0.60 0.90 Q3 '24: -0.85 Q4 '24: -0.38 Q1 '25: -0.04 Q2 '25: 0.01 Q3 '25: 0.02 Q4 '25: 0.23 Q1 '26: 0.38 Q2 '26: 0.49 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.